Edwards Lifesciences said on July 21, 2025 that Larry L. Wood notified the Board of Directors of his resignation from his position as Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart.

1. 01

   Edwards Lifesciences said on July 21, 2025 that Larry L. Wood notified the Board of Directors of his resignation from his position as Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart.

2. 02

   The company said Wood's resignation is effective September 1, 2025 and that he is accepting a senior leadership position at another company outside cardiovascular.

3. 03

   Edwards Lifesciences said that effective September 1, 2025, Daniel J. Lippis, the company's current Corporate Vice President, Japan, Greater China and Asia Pacific, will serve as Corporate Vice President responsible for Transcatheter Aortic Valve Replacement.

4. 04

   The company listed the date of the earliest event reported in this 8-K as July 21, 2025 and disclosed the matter under Item 5.02 regarding departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.